

ABSTRACT OF THE DISCLOSURE

Compounds of the formula (I), wherein: -X=Y- is selected from -CR₂=CR₃- and -CR₂=N-; R₁ is selected from H, halo, NRR', NHC(=O)R, NHC(=O)NRR', NH₂SO₂R, and C(=O)NRR'; R₂ and R₃ (where present) are independently selected from H, optionally substituted C₁₋₇ alkyl, optionally substituted C₅₋₂₀ aryl, optionally substituted C₃₋₂₀ heterocyclyl, halo, amino, amido, hydroxy, ether, thio, thioether, acylamido, ureido and sulfonamino; R₄ is an optionally substituted C₅₋₂₀ aryl or C₅₋₂₀ heteroaryl group; and R₅ is selected from R_{5'}, halo, NHR_{5'}, C(=O)NHR_{5'}, OR_{5'}, SR_{5'}, NHC(=O)R_{5'}, NHC(=O)NHR_{5'}, NHS(=O)R_{5'}, wherein R_{5'} is H or C₁₋₃ alkyl (optionally substituted by halo, NH₂, OH, SH) are disclosed for use in therapy and for treating diseases ameliorated by inhibiting p38 MAP kinase.